Martin D. Madaus Buys 1,800 Shares of Repligen Corporation (NASDAQ:RGEN) Stock

Key Points

• Martin D. Madaus, a director at Repligen Corporation, purchased 1,800 shares of the company's stock for a total of $201,834 at an average price of $112.13 per share.
• Repligen's latest quarterly earnings report revealed a 14.8% increase in revenue year-over-year, but earnings per share fell short of analysts' expectations.
• Most equities analysts currently rate Repligen with a consensus "Moderate Buy" and an average target price of $169.45.

Repligen Corporation (NASDAQ:RGEN - Get Free Report) Director Martin D. Madaus acquired 1,800 shares of the stock in a transaction that occurred on Friday, August 8th. The stock was purchased at an average cost of $112.13 per share, with a total value of $201,834.00. Following the completion of the acquisition, the director owned 1,800 shares of the company's stock, valued at $201,834. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Repligen Price Performance

RGEN traded up $7.92 during trading on Tuesday, reaching $119.80. The stock had a trading volume of 590,810 shares, compared to its average volume of 781,240. The firm has a market capitalization of $6.74 billion, a price-to-earnings ratio of -479.48, a price-to-earnings-growth ratio of 2.05 and a beta of 1.05. The company has a quick ratio of 7.32, a current ratio of 8.59 and a debt-to-equity ratio of 0.26. Repligen Corporation has a 1-year low of $102.96 and a 1-year high of $182.52. The stock has a 50 day moving average of $122.63 and a two-hundred day moving average of $133.75.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported $0.37 EPS for the quarter, missing analysts' consensus estimates of $0.40 by ($0.03). Repligen had a negative net margin of 2.05% and a positive return on equity of 4.61%. The company had revenue of $182.37 million for the quarter, compared to analyst estimates of $174.62 million. During the same quarter last year, the company posted $0.40 EPS. Repligen's revenue was up 14.8% on a year-over-year basis. As a group, equities analysts anticipate that Repligen Corporation will post 1.72 EPS for the current fiscal year.

Institutional Trading of Repligen

Several large investors have recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD increased its position in Repligen by 11.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,136,054 shares of the biotechnology company's stock worth $1,027,165,000 after buying an additional 743,815 shares during the last quarter. Point72 Asset Management L.P. increased its position in Repligen by 183.1% during the fourth quarter. Point72 Asset Management L.P. now owns 918,623 shares of the biotechnology company's stock worth $132,227,000 after buying an additional 594,189 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its position in Repligen by 3,219.3% during the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 413,425 shares of the biotechnology company's stock worth $51,422,000 after buying an additional 400,970 shares during the last quarter. Alyeska Investment Group L.P. acquired a new position in Repligen during the fourth quarter worth $53,428,000. Finally, Raymond James Financial Inc. bought a new stake in Repligen during the fourth quarter valued at about $52,492,000. 97.64% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. Wells Fargo & Company lowered their target price on Repligen from $180.00 to $175.00 and set an "overweight" rating for the company in a report on Wednesday, July 30th. Wolfe Research raised Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 target price for the company in a report on Tuesday, April 29th. Stephens raised Repligen to an "overweight" rating and set a $160.00 price objective for the company in a report on Tuesday, July 22nd. Wall Street Zen lowered Repligen from a "buy" rating to a "hold" rating in a report on Sunday, June 29th. Finally, Evercore ISI decreased their price objective on Repligen from $140.00 to $130.00 and set an "in-line" rating for the company in a report on Tuesday, July 8th. Four research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $169.45.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.